obesity drug news today glp-1 october 2025 The world is desperate for weight-loss drugs. But Big Pharma can't advertise them GLP-1 Pipeline Update: August 2025

Consistent with earlier studies, side effects emerged as the most commonly cited reason for discontinuation, regardless of medication indication

A woman who is GSTM1 null faces depleted glutathione conjugation capacity for both estrogen quinones and environmentally-derived reactive metabolites simultaneously a compounded oxidative burden that blood panels cannot quantify but genetics surfaces as a baseline predisposition

On the highest 12 mg dose, participants lost an average of 28.3% of their body weight, equivalent to approximately 70.3 pounds

Neuropharmacology, 101, 3645

A transient, focal neurologic deficit is important for two reasons: (1) This supports that the event was truly a seizure

Cellular Penetration Lipo-GSH mechanism : Upon contact with cell membranes, liposomes deliver GSH into cells via adsorption, endocytosis, or membrane fusion